Skip to content

INMED PHARMACEUTICALS INC.: 10-Q filed 2025-05-12

What INMED PHARMACEUTICALS INC. reported in its quarterly report filed 2025-05-12 (fiscal Q3 2025): 42 published measures, 120 facts as tagged in accession 0001213900-25-042126.

This filing

Form
10-Q (quarterly report)
Filed
2025-05-12
Fiscal period
fiscal Q3 2025
Accession
0001213900-25-042126 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All INMED PHARMACEUTICALS INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2025-03-319,279,834USD
At 2024-06-3011,822,782USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2025-03-312,258,309USD
At 2024-06-302,616,673USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2025-03-317,021,525USD
At 2024-12-316,182,100USD
At 2024-09-308,395,444USD
At 2024-06-309,206,109USD
At 2024-03-3111,104,650USD
At 2023-12-3112,772,211USD
At 2023-09-30-9,578,090USD
At 2023-06-3012,089,727USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2025-03-314,679,826USD
At 2024-06-306,571,610USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2025-01-01 to 2025-03-31-2,120,930USD90
2024-07-01 to 2025-03-31-6,373,822USD274
2024-10-01 to 2024-12-31-2,575,024USD92
2024-07-01 to 2024-09-30-1,677,868USD92
2024-01-01 to 2024-03-31-1,722,866USD91
2023-07-01 to 2024-03-31-5,737,879USD275
2023-10-01 to 2023-12-31-1,478,185USD92
2023-07-01 to 2023-09-30-2,536,828USD92

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2024-07-01 to 2025-03-31-5,988,445USD274
2023-07-01 to 2024-03-31-5,956,668USD275

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2023-07-01 to 2024-03-319,293USD275

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2025-01-01 to 2025-03-311,261,578USD90
2024-07-01 to 2025-03-313,637,923USD274
2024-01-01 to 2024-03-311,172,601USD91
2023-07-01 to 2024-03-313,314,663USD275

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2024-07-01 to 2025-03-314,096,661USD274
2023-07-01 to 2024-03-314,654,042USD275

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2023-07-01 to 2024-03-31-9,293USD275

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2025-03-31-115,449,581USD
At 2024-06-30-109,075,759USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2025-01-01 to 2025-03-311,095,973shares90
2024-07-01 to 2025-03-31803,909shares274
2024-01-01 to 2024-03-31480,649shares91
2023-07-01 to 2024-03-31348,097shares275

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2025-01-01 to 2025-03-311,095,973shares90
2024-07-01 to 2025-03-31803,909shares274
2024-01-01 to 2024-03-31480,649shares91
2023-07-01 to 2024-03-31348,097shares275

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2025-01-01 to 2025-03-31-1.94USD/shares90
2024-07-01 to 2025-03-31-7.93USD/shares274
2024-01-01 to 2024-03-31-3.58USD/shares91
2023-07-01 to 2024-03-31-16.48USD/shares275

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2025-01-01 to 2025-03-31-1.94USD/shares90
2024-07-01 to 2025-03-31-7.93USD/shares274
2024-01-01 to 2024-03-31-3.58USD/shares91
2023-07-01 to 2024-03-31-16.48USD/shares275

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2025-03-311,108,662USD
At 2024-06-301,249,999USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2024-07-01 to 2025-03-3192,577USD274
2023-07-01 to 2024-03-3198,760USD275

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2025-03-316,410,063USD
At 2024-06-308,689,585USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2025-03-311,838,962USD
At 2024-06-301,971,808USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2025-03-311,661,109USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2025-03-31367,813USD
At 2024-06-30352,838USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2025-01-01 to 2025-03-312,313,120USD90
2024-07-01 to 2025-03-317,256,400USD274
2024-01-01 to 2024-03-312,133,782USD91
2023-07-01 to 2024-03-316,796,982USD275

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2025-03-31813,970USD
At 2024-06-301,244,324USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2025-01-01 to 2025-03-31175,625USD90
2024-07-01 to 2025-03-311,129,932USD274
2024-01-01 to 2024-03-31289,458USD91
2023-07-01 to 2024-03-31634,842USD275

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2025-01-01 to 2025-03-311,085,953USD90
2024-07-01 to 2025-03-312,507,991USD274
2024-01-01 to 2024-03-31883,143USD91
2023-07-01 to 2024-03-312,679,821USD275

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2025-01-01 to 2025-03-31909,653USD90
2024-07-01 to 2025-03-312,741,200USD274
2024-01-01 to 2024-03-31656,764USD91
2023-07-01 to 2024-03-312,558,648USD275

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2025-03-311,207,186shares
At 2024-06-30445,908shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2025-03-314,679,826USD
At 2024-06-306,571,610USD
At 2024-03-317,600,598USD
At 2023-06-308,912,517USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2025-03-31128,569USD
At 2024-06-30128,569USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2025-03-31848,594USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2025-03-312,320,100USD
At 2024-06-302,605,310USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2025-03-311,211,438USD
At 2024-06-301,355,311USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2025-03-311,661,109USD
At 2024-06-301,783,198USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2025-03-31100,000USD
At 2024-06-30100,000USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2025-03-31507,872USD
At 2024-06-30477,749USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2025-01-01 to 2025-03-31-2,120,930USD90
2024-07-01 to 2025-03-31-6,373,822USD274
2024-01-01 to 2024-03-31-1,722,866USD91
2023-07-01 to 2024-03-31-5,737,879USD275

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2025-01-01 to 2025-03-311,328,996USD90
2024-07-01 to 2025-03-314,304,505USD274
2024-01-01 to 2024-03-311,374,095USD91
2023-07-01 to 2024-03-314,036,784USD275

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2025-01-01 to 2025-03-3112,203USD90
2024-07-01 to 2025-03-3137,998USD274
2024-01-01 to 2024-03-3114,220USD91
2023-07-01 to 2024-03-3142,302USD275

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2024-07-01 to 2025-03-31160,087USD274
2023-07-01 to 2024-03-31164,833USD275

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2025-01-01 to 2025-03-3140,103USD90
2024-07-01 to 2025-03-31122,089USD274
2024-01-01 to 2024-03-3140,993USD91
2023-07-01 to 2024-03-31122,531USD275

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2024-07-01 to 2025-03-3114,975USD274
2023-07-01 to 2024-03-31-52,718USD275

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2024-07-01 to 2025-03-31-430,354USD274
2023-07-01 to 2024-03-31-159,000USD275

Inspect the source

Entity
INMED PHARMACEUTICALS INC. / CIK 0001728328
Captured
2026-09-21T17:27:41.396Z
SEC response SHA-256
1f73e76cc8d3847e3658f72033c4ed33ce1de4528067a6f82d159b8aa5c1b91f

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001728328.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))